FDA Gets Senate Funding, House Scolding In Fiscal 2015 Appropriation
This article was originally published in The Tan Sheet
Executive Summary
An omnibus spending agreement gives FDA about a 1.3% increase from its fiscal 2014 appropriation. But the Office of the Commissioner still stands to lose $20 million if FDA does not finalize draft guidance on evaluation and labeling of abuse-deterrent opioids by June 30, 2015.
You may also be interested in...
Ebola Treatments Could Be Orphan Candidates – But Vaccines, Probably Not
FDA expects few people would get the disease in the U.S., but many could receive a vaccine.
FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling
Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.